Pathogenic roles of anti-β2-GPI antibody in patients with antiphospholipid syndrome

Japanese Journal of Clinical Immunology

Volumn 27, Issue 6, 2004, Pages 373-378

  Yasuda, Shinsuke ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

atherosclerosis; complement cascade; p38 MAPK; protein C; thromhosis

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; GLYCOPROTEIN;

ANTIPHOSPHOLIPID SYNDROME; HUMAN; IMMUNOLOGY; REVIEW;

ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; GLYCOPROTEINS; HUMANS;

EID: 17144372212     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.27.373     Document Type: Article

References (27)

1. McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S.A.: Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87(11): 4120–4124, 1990.
2. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T.: Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336(8708): 177–178, 1990.
3. Pierangeli S. S., Liu S. W., Anderson G., Barker J. H., Harris E.N.: Thrombogenic properties of murine anticardiolipin antibodies induced by β2-glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 94 (7): 1746–1751, 1996.
4. Jurado M., Paramo J. A., Gutierrez-Pimentel M., Rocha E.: Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 68(5): 516–520, 1992.
5. Ames P. R., Tommasino C., Iannaccone L., Brillante M., Cimino R., Brancaccio V.: Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies-a crucial role for acquired free protein S deficiency. Thromb Haemost 76(2): 190–194, 1996.
6. Atsumi T., Khamashta M. A., Andujar C., Leandro M. J., Amengual O., Ames P.R. et al.: Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 25 (1): 69–73, 1998.
7. Bouma B., de Groot P. G., van den Elsen J. M., Ravelli R. B., Schouten A., Simmelink M.J. et al.: Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 18(19): 5166–5174, 1999.
8. Shi T., Iverson G. M., Qi J. C., Cockerill K. A., Linnik M. D., Konecny P. et al.: β2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci USA 101(11): 3939–3944, 2004.
9. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T.: Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107 (3): 569–573, 1997.
10. Yasuda S., Tsutsumi A., Chiba H., Yanai H., Miyoshi Y., Takeuchi R. et al.: β2-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152(2): 337–346, 2000.
11. Takeuchi R., Atsumi T., Ieko M., Takeya H., Yasuda S., Ichikawa K. et al.: Coagulation and fibrinolytic activities in 2 siblings with β2-glycoprotein I deficiency. Blood 96(4): 1594–1595, 2000.
12. Matsuura E., Igarashi Y., Yasuda T., Triplett D. A., Koike T.: Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179(2): 457–62, 1994.
13. Iverson G. M., Victoria E. J., Marquis D.M. Anti-β2-glycoprotein I (β2-GPI) autoantibodies recognize an epitope on the first domain of β2-GPI. Proc Natl Acad Sci USA 95(26): 15542–15546, 1998.
14. Koike T., Ichikawa K., Atsumi T., Kasahara H., Matsuura E.: β2-glycoprotein I-anti-β2-glycoprotein I interaction. J Autoimmun 15 (2): 97–100, 2000.
15. Yasuda S., Atsumi T., Matsuura E., Kaihara K., Yamamoto D., Ichikawa K. et al.: Significance of Valine/leucine247 Polymorphism of β2-glycoprotein I in Antiphospholipid Syndrome: Increaed Reactivity of anti-β2-glycoprotein I autoantibodies to the Valine247 β2-glycoprotein I Variant. Arthritis Rheum (in press).
16. Kuwana M.: Autoreactive CD4(+) T cells to β2-glycoprotein I in patients with antiphospholipid syndrome. Autoimmun Rev 2 (4): 192–198, 2003.
17. Mauduit G., Souteyrand P., Thivolet J.: [Antiprothrombinase type of circulating anticoagulants during acute disseminated lupus erythematosus]. Ann Dermatol Venereol 109 (6–7): 557–564, 1982.
18. Ieko M., Ichikawa K., Triplett D. A., Matsuura E., Atsumi T., Sawada K. et al.: β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 42(1): 167–174, 1999.
19. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T.: Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107 (3): 569–573, 1997.
20. Lopez D., Garcia-Valladares I., Palafox-Sanchez C. A., De L. T. I., Kobayashi K., Matsuura E. et al.: Oxidized low-density lipoprotein / β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 121 (3): 426–436, 2004.
21. Lutters B. C., Derksen R. H., Tekelenburg W. L., Lenting P. J., Arnout J., de Groot P.G.: Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 278(36): 33831–33838, 2003.
22. Amengual O., Atsumi T., Khamashta M. A., Hughes G.R.: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79(2): 276–281, 1998.
23. Meroni P. L., Raschi E., Testoni C., Tincani A., Balestrieri G., Molteni R. et al.: Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44(12): 2870–2878, 2001.
24. Raschi E., Testoni C., Bosisio D., Borghi M. O., Koike T., Mantovani A. et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101(9): 3495–3500, 2003.
25. Bohgaki M., Atsumi T., Yamashita Y., Yasuda S., Sakai Y., Furusaki A. et al.: The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-(beta)2Glycoprotein I antibodies. Int Immunol 16(11): 1633–1641, 2004.
26. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M. et al.: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrom. J Clin Invest 112 (11): 1644–1654, 2004.
27. Girardi G., Redecha P., Salmon J.E.: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 10(11): 1222–1226, 2004.